Berliner Boersenzeitung - Ozempic-maker Novo Nordisk says CEO to step down

EUR -
AED 4.247849
AFN 81.535676
ALL 99.229693
AMD 443.817196
ANG 2.069694
AOA 1059.352541
ARS 1367.299246
AUD 1.772697
AWG 2.084587
AZN 1.961645
BAM 1.953119
BBD 2.333976
BDT 141.380844
BGN 1.953671
BHD 0.436063
BIF 3402.416229
BMD 1.156498
BND 1.479982
BOB 8.005082
BRL 6.35125
BSD 1.155904
BTN 99.410418
BWP 15.43395
BYN 3.782975
BYR 22667.354891
BZD 2.321933
CAD 1.569541
CDF 3327.243584
CHF 0.941378
CLF 0.028234
CLP 1083.46511
CNY 8.303364
CNH 8.304555
COP 4746.266555
CRC 582.695208
CUC 1.156498
CUP 30.647189
CVE 110.590075
CZK 24.799706
DJF 205.532586
DKK 7.458214
DOP 68.522692
DZD 150.10418
EGP 58.134884
ERN 17.347465
ETB 155.317484
FJD 2.597783
FKP 0.85151
GBP 0.852032
GEL 3.168501
GGP 0.85151
GHS 11.883006
GIP 0.85151
GMD 82.685047
GNF 10010.644422
GTQ 8.88373
GYD 241.840164
HKD 9.078334
HNL 30.191554
HRK 7.536668
HTG 151.271071
HUF 402.611717
IDR 18816.448855
ILS 4.031915
IMP 0.85151
INR 99.577285
IQD 1515.011985
IRR 48700.118365
ISK 143.645957
JEP 0.85151
JMD 184.501556
JOD 0.819968
JPY 167.385656
KES 149.769917
KGS 101.135651
KHR 4649.120623
KMF 492.088049
KPW 1040.847929
KRW 1572.443983
KWD 0.35397
KYD 0.963286
KZT 592.781278
LAK 25069.97561
LBP 103622.194
LKR 348.04929
LRD 230.894858
LSL 20.608803
LTL 3.414837
LVL 0.699554
LYD 6.274023
MAD 10.55015
MDL 19.767041
MGA 5129.067546
MKD 61.554151
MMK 2428.538524
MNT 4141.704966
MOP 9.346553
MRU 45.878322
MUR 52.391637
MVR 17.81587
MWK 2007.680345
MXN 21.878219
MYR 4.904129
MZN 73.957813
NAD 20.608655
NGN 1784.464341
NIO 41.981214
NOK 11.465868
NPR 159.057068
NZD 1.908198
OMR 0.444677
PAB 1.155923
PEN 4.166891
PGK 4.76697
PHP 64.955881
PKR 327.405107
PLN 4.269905
PYG 9221.264014
QAR 4.210232
RON 5.02047
RSD 117.211348
RUB 90.944119
RWF 1648.00922
SAR 4.339355
SBD 9.653738
SCR 16.971569
SDG 694.472825
SEK 10.97644
SGD 1.480429
SHP 0.908826
SLE 25.703134
SLL 24251.182727
SOS 660.944303
SRD 44.803824
STD 23937.1674
SVC 10.114468
SYP 15036.671822
SZL 20.608561
THB 37.505595
TJS 11.710081
TMT 4.047742
TND 3.379868
TOP 2.708637
TRY 45.553637
TTD 7.847297
TWD 34.023583
TZS 2983.107141
UAH 48.060998
UGX 4167.280377
USD 1.156498
UYU 47.266761
UZS 14788.718721
VES 118.155902
VND 30140.06477
VUV 137.741738
WST 3.029085
XAF 655.063585
XAG 0.031842
XAU 0.000342
XCD 3.125493
XDR 0.817945
XOF 653.420822
XPF 119.331742
YER 280.970872
ZAR 20.597282
ZMK 10409.870605
ZMW 28.031769
ZWL 372.391787
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Ozempic-maker Novo Nordisk says CEO to step down
Ozempic-maker Novo Nordisk says CEO to step down / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File

Ozempic-maker Novo Nordisk says CEO to step down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Text size:

The company said the decision was made by mutual agreement with the board and that it was searching for a successor for Lars Fruergaard Jorgensen.

Jorgensen will continue "for a period to support a smooth transition to new leadership", Novo Nordisk said in a statement.

The change is being made "in light of the recent market challenges Novo Nordisk has been facing and the development of the company's share price since mid-2024", it said.

At the same time, the company stressed the success it had seen under Jorgensen's stewardship.

"During his eight-year tenure as CEO, Novo Nordisk's sales, profits and share price have almost tripled," Novo Nordisk said.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago.

Ozempic, which accounts for 41 percent of Novo Nordisk's sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Novo Nordisk launched the anti-obesity drug Wegovy, which uses the same molecule but has been directly approved as a weight loss treatment, in the United States in 2021.

Following the success of its treatments, Novo Nordisk rose to become Europe's most valuable company by market capitalisation in September 2023, overtaking French luxury fashion house LVMH, making the company a cornerstone of the Danish economy.

The drugmaker has since been dethroned and reclaimed the spot several times, having last been overtaken for the lead by German tech company SAP in March.

- Facing competition -

Since June 2024, Novo Nordisk's share has fallen by more than half and now ranks as Europe's fourth most valuable company.

The share price dropped more than three percent on the Copenhagen stock exchange following Friday's announcement.

The decline has come as its dominant position has faced several challenges.

Earlier this month, the company cut its full-year sales growth forecast due to competition from copycat versions of its popular GLP-1 injections made in US pharmacies -- a practice known as compounding.

The pharmacies had been allowed to make their own version of Wegovy and Ozempic due to a shortage of the drugs.

But US regulators ruled in February that the shortage had ended and ordered pharmacies to discontinue making the compounded versions.

"We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments," Jorgensen said in a statement in early May.

The Danish group had cut its sales forecast from the 16-to-24 percent range to 13-to-21 percent.

Novo Nordisk is also facing competition from US rival Eli Lilly, which makes the anti-obesity injection Zepbound.

Novo Nordisk's shares tumbled last month after Eli Lilly announced a successful clinical trial of diabetes and obesity treatment orforglipron.

Around the world, more than 10 percent of the population suffers from diabetes, for which treatments make up the core of the drugmaker's business.

According to the International Diabetes Federation, the number of diabetic adults is expected to increase by 46 percent by 2045.

The World Obesity Federation also predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.

(A.Lehmann--BBZ)